Business Context and Reporting Period
This Form 8-K is filed by Xcyte Therapies, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of October 4, 2005. The filing discloses the entry into definitive material agreements regarding executive compensation, severance, and acquisition bonuses.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific contractual obligations:
- Severance Payment: $222,692.32 (lump sum to former CEO Ronald J. Berenson, less taxes).
- COBRA Benefits: Up to $12,634 (for Dr. Berenson through June 30, 2006).
- Acquisition Bonus (Dr. Kirkman): $150,000 (contingent on change of control).
- Severance (Dr. Kirkman): $150,000 (contingent on termination without cause or for good reason around a change of control).
- Acquisition Bonus (Dr. Henney): $250,000 (contingent on change of control).
Material Changes
The primary material change is the execution of three new agreements on October 4 and 5, 2005:
- Separation of Former CEO: Dr. Ronald J. Berenson, who served as President and CEO from 1996 to June 2005, has entered a separation agreement. He will receive severance equivalent to nine months of base salary but will remain on the Board of Directors.
- Acting CEO Compensation: Dr. Robert L. Kirkman, Acting President and CEO, received an agreement providing for a $150,000 bonus upon a change of control and severance under similar conditions.
- Chairman Bonus: Dr. Christopher S. Henney, Chairman of the Board, received an agreement for a $250,000 bonus upon a change of control.
Outlook, Risks, and Contingencies
Contingencies: The payments to Dr. Kirkman and Dr. Henney are strictly contingent upon the consummation of a merger, acquisition, or change of control. The severance for Dr. Kirkman is also contingent on specific termination scenarios occurring within a defined window relative to a change of control.
Risks: The filing highlights potential cash outflows if a change of control occurs, totaling up to $400,000 in bonuses for the Acting CEO and Chairman, plus the immediate severance obligation for the former CEO.
Management Commentary: The filing contains no forward-looking guidance regarding business operations or financial performance beyond the terms of the disclosed agreements.
Investor Verification Checklist
- Verify the total immediate cash impact of the $222,692.32 severance payment on the company's current liquidity.
- Confirm the status of the Board of Directors following the departure of Dr. Berenson as CEO, noting he remains a director.
- Assess the potential liability exposure of $400,000 in acquisition bonuses should a change of control transaction be initiated.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific definitions of "good reason" and "without cause" regarding Dr. Kirkman's severance.